Precision BioSciences gets clearance for additional PBGENE-DMD trial dosing after safety review
DTIL•Precision BioSciences can dose additional patients in its Phase 1/2 FUNCTION-DMD trial after an independent safety review found no safety concerns in the first patient through eight weeks. The company plans safety and efficacy updates throughout 2027.
1. Dosing clearance
An independent safety review found no safety concerns in the first patient through eight weeks, allowing Precision BioSciences to dose additional patients in Part 1 of its Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD for Duchenne muscular dystrophy. Safety and efficacy updates are planned throughout 2027.
